共查询到20条相似文献,搜索用时 31 毫秒
1.
2.
3.
Azzout-Marniche D Gaudichon C Blouet C Bos C Mathé V Huneau JF Tomé D 《American journal of physiology. Regulatory, integrative and comparative physiology》2007,292(4):R1400-R1407
This paper provides molecular evidence for a liver glyconeogenic pathway, that is, a concomitant activation of hepatic gluconeogenesis and glycogenesis, which could participate in the mechanisms that cope with amino acid excess in high-protein (HP) fed rats. This evidence is based on the concomitant upregulation of phosphoenolpyruvate carboxykinase (PEPCK) gene expression, downregulation of glucose 6-phosphatase catalytic subunit (G6PC1) gene expression, an absence of glucose release from isolated hepatocytes and restored hepatic glycogen stores in the fed state in HP fed rats. These effects are mainly due to the ability of high physiological concentrations of portal blood amino acids to counteract glucagon-induced liver G6PC1 but not PEPCK gene expression. These results agree with the idea that the metabolic pathway involved in glycogen synthesis is dependent upon the pattern of nutrient availability. This nonoxidative glyconeogenic disposal pathway of gluconeogenic substrates copes with amino excess and participates in adjusting both amino acid and glucose homeostasis. In addition, the pattern of PEPCK and G6PC1 gene expression provides evidence that neither the kidney nor the small intestine participated in gluconeogenic glucose production under our experimental conditions. Moreover, the main glucose-6-phosphatase (G6Pase) isoform expressed in the small intestine is the ubiquitous isoform of G6Pase (G6PC3) rather than the G6PC1 isoform expressed in gluconeogenic organs. 相似文献
4.
5.
Chanda D Kim SJ Lee IK Shong M Choi HS 《American journal of physiology. Endocrinology and metabolism》2008,295(2):E368-E379
Sodium arsenite has been demonstrated to alter the expression of genes associated with glucose homeostasis in tissues involved in the pathogenesis of type 2 diabetes; however, the underlying molecular mechanism has not been fully elucidated yet. In this study, we report that the sodium arsenite-induced gene expression of the small heterodimer partner (SHP; NR0B2), an atypical orphan nuclear receptor, regulates the expression of hepatic gluconeogenic genes. Sodium arsenite augments hepatic SHP mRNA levels in an AMP-activated protein kinase (AMPK)-dependent manner. Sodium arsenite activated AMPK and was shown to perturb cellular ATP levels. The arsenite-induced SHP mRNA level was blocked by adenoviral overexpression of dominant negative AMPK (Ad-dnAMPKalpha) or by the AMPK inhibitor compound C in hepatic cell lines. We demonstrated the dose-dependent induction of SHP mRNA levels by sodium arsenite and repressed the forskolin/dexamethasone-induced gene expression of the key hepatic gluconeogenic genes phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase). Ad-dnAMPKalpha blocked the repressive effects of arsenite-induced SHP on PEPCK and G6Pase. Sodium arsenite inhibited the promoter activity of PEPCK and G6Pase, and this repression was abolished by small interfering (si)RNA SHP treatments. The knockdown of SHP expression by oligonucleotide siRNA SHP or adenoviral siRNA SHP released the sodium arsenite-mediated repression of forskolin/dexamethasone-stimulated PEPCK and G6Pase gene expression in a variety of hepatic cell lines. Results from our study suggest that sodium arsenite induces SHP via AMPK to inhibit the expression of hepatic gluconeogenic genes and also provide us with a novel molecular mechanism of arsenite-mediated regulation of hepatic glucose homeostasis. 相似文献
6.
7.
8.
9.
Wang Y Oeser JK Yang C Sarkar S Hackl SI Hasty AH McGuinness OP Paradee W Hutton JC Powell DR O'Brien RM 《The Journal of biological chemistry》2006,281(52):39982-39989
In liver, glucose-6-phosphatase catalyzes the hydrolysis of glucose-6-phosphate (G6P) to glucose and inorganic phosphate, the final step in the gluconeogenic and glycogenolytic pathways. Mutations in the glucose-6-phosphatase catalytic subunit (G6Pase) give rise to glycogen storage disease (GSD) type 1a, which is characterized in part by hypoglycemia, growth retardation, hypertriglyceridemia, hypercholesterolemia, and hepatic glycogen accumulation. Recently, a novel G6Pase isoform was identified, designated UGRP/G6Pase-beta. The activity of UGRP relative to G6Pase in vitro is disputed, raising the question as to whether G6P is a physiologically important substrate for this protein. To address this issue we have characterized the phenotype of UGRP knock-out mice. G6P hydrolytic activity was decreased by approximately 50% in homogenates of UGRP(-/-) mouse brain relative to wild type tissue, consistent with the ability of UGRP to hydrolyze G6P. In addition, female, but not male, UGRP(-/-) mice exhibit growth retardation as do G6Pase(-/-) mice and patients with GSD type 1a. However, in contrast to G6Pase(-/-) mice and patients with GSD type 1a, UGRP(-/-) mice exhibit no change in hepatic glycogen content, blood glucose, or triglyceride levels. Although UGRP(-/-) mice are not hypoglycemic, female UGRP(-/-) mice have elevated ( approximately 60%) plasma glucagon and reduced ( approximately 20%) plasma cholesterol. We hypothesize that the hyperglucagonemia prevents hypoglycemia and that the hypocholesterolemia is secondary to the hyperglucagonemia. As such, the phenotype of UGRP(-/-) mice is mild, indicating that G6Pase is the major glucose-6-phosphatase of physiological importance for glucose homeostasis in vivo. 相似文献
10.
Park JM Kim TH Bae JS Kim MY Kim KS Ahn YH 《Biochemical and biophysical research communications》2010,403(3-4):329-334
During a state of fasting, the blood glucose level is maintained by hepatic gluconeogenesis. SIRT1 is an important metabolic regulator during nutrient deprivation and the liver-specific knockdown of SIRT1 resulted in decreased glucose production. We hypothesize that SIRT1 is responsible for the upregulation of insulin-suppressed gluconeogenic genes through the deacetylation of FOXO1. Treatment of primary cultured hepatocytes with resveratrol increased insulin-repressed PEPCK and G6Pase mRNA levels, which depend on SIRT1 activity. We found that the resveratrol treatment resulted in a decrease in the phosphorylation of Akt and FOXO1, which are independent of SIRT1 action. Fluorescence microscopy revealed that resveratrol caused the nuclear localization of FOXO1. In the nucleus, FOXO1 is deacetylated by SIRT1, which might make it more accessible to the IRE of the PEPCK and G6Pase promoter, causing an increase in their gene expression. Our results indicate that resveratrol upregulates the expression of gluconeogenic genes by attenuating insulin signaling and by deacetylating FOXO1, which are SIRT1-independent in the cytosol and SIRT1-dependent in the nucleus, respectively. 相似文献
11.
12.
13.
Panserat S Capilla E Gutierrez J Frappart PO Vachot C Plagnes-Juan E Aguirre P Brèque J Kaushik S 《Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology》2001,128(2):275-283
The low dietary starch utilisation by rainbow trout (Oncorhynchus mykiss) may be attributed to a dysfunction of the nutritional regulation of the hepatic glucose/glucose-6-phosphate cycle. The present study was initiated to analyse the regulation of activity and gene expression of hepatic glucokinase (GK) and glucose-6-phosphatase (G6Pase) by dietary carbohydrates in this species. We found that even a single meal containing 24% of glucose is sufficient to induce the GK expression (mRNA and activity) as in mammals. In contrast, although the inhibitory effect of dietary glucose on G6Pase expression is observed at the molecular level, the G6Pase activity is not significantly inhibited by dietary glucose. Thus, in contrast to the gluconeogenic G6Pase enzyme, a rapid adaptation of the hepatic glycolytic GK enzyme to dietary glucose seems effective in rainbow trout. These results suggest that in carnivorous rainbow trout, the liver is capable to strongly regulate the utilisation of glucose but not the synthesis of glucose. 相似文献
14.
《Chronobiology international》2013,30(7):815-828
Daytime restricted feeding (DRF) promotes circadian adaptations in the metabolic processing of nutrients. We explored the hepatic gluconeogenic response in DRF rats by the temporal profiles of the following: (1) the activity of glucose 6-phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK), as well as the periportal and pericentral distribution of PEPCK; (2) conversion of alanine to glucose; (3) glycemia and liver glycogen content; (4) presence of glycogen synthase (GYS) and its phosphorylated form (at Ser641, pGYS); (5) circulating levels of corticosterone, glucagon and insulin; (6) glucose-tolerance test; and (7) sirtuin 1 (SIRT1) and peroxisome proliferator-activated receptor-coactivator 1α (PGC-1α). The results showed that DRF promoted: (1) a phase shift in G6Pase activity and an increase in PEPCK activity as well as a change of PEPCK from periportal to pericentral hepatocytes, (2) a net conversion of alanine to circulating glucose, (3) a decrease in glycemic values and a phase shift in the liver glycogen content, (4) a phase shift in GYS and an increase of pGYS, (5) an increase in the daily levels of corticosterone and glucagon, but a reduction in the levels of insulin, (6) normal glucose homeostasis in all groups and (7) an enhanced presence of SIRT1 and PGC-1α. It is proposed that the increased gluconeogenic in DRF group promotes synthesis of hepatic glycogen and the production of glucose. These results could be a modulation of the gluconeogenic process due to rheostatic adaptations in the endocrine, metabolic and timing regulation of liver and could be associated with the physiology of the food entrained oscillator. 相似文献
15.
Kirchner S Panserat S Lim PL Kaushik S Ferraris RP 《Journal of comparative physiology. B, Biochemical, systemic, and environmental physiology》2008,178(3):429-438
Rainbow trout is unable to utilize high levels of dietary carbohydrates and experiences hyperglycemia after consumption of
carbohydrate-rich meals. Carbohydrates stimulate hepatic glycolytic activity, but gene expression of the rate-limiting gluconeogenic
enzymes glucose-6-phosphatase (G6Pase), fructose-1,6-bisphosphatase (FBPase) and phosphoenolpyruvate carboxykinase (PEPCK)
remains high. Although there is significant mRNA expression and activity of gluconeogenic enzymes in trout intestine and kidney,
the regulation of these enzymes by diet is not known. We tested the hypothesis that dietary carbohydrate modulates intestinal
and renal G6Pase, FBPase and PEPCK. Fish were either fasted or fed isocaloric carbohydrate-free (CF) or high carbohydrate
(HC) diets for 14 days. As expected, fish fed HC exhibited postprandial hyperglycemia and enhanced levels of hepatic glucokinase
mRNA and activity. Dietary carbohydrates had no significant effect on the expression and activity of PEPCK, FBPase and G6Pase
in all three organs. In contrast, fasting enhanced the activity, but not the mRNA expression of both hepatic and intestinal
PEPCK, as well as intestinal FBPase. Therefore, the activity of rate-limiting gluconeogenic enzymes in trout can be modified
by fasting, but not by the carbohydrate content of the diet, potentially causing hyperglycemia when fed high levels of dietary
carbohydrates. In this species consuming low carbohydrate diets at infrequent intervals in the wild, fasting-induced increases
in hepatic and intestinal gluconeogenic enzyme activities may be a key adaptation to prevent perturbations in blood glucose
during food deprivation.
Presented in part at Experimental Biology, April 2006, San Francisco, CA [Kirchner S., Panserat S., Kaushik S. and Ferraris
R. FASEB-IUPS-2006 A667.6]. 相似文献
16.
Our objective is to understand the low metabolic utilization of dietary carbohydrates in fish. We compared the regulation of gluconeogenic enzymes at a molecular level in two fish species, the common carp (Cyprinus carpio) and gilthead seabream (Sparus aurata), known to be relatively tolerant to dietary carbohydrates. After cloning of partial cDNA sequences for three key gluconeogenic enzymes (glucose-6-phosphatase (G6Pase), fructose biphosphatase (FBPase) and phosphoenolpyruvate carboxykinase (PEPCK) in the two species, we analyzed gene expressions of these enzymes 6 and 24 h after feeding with (20%) or without carbohydrates. Our data show that there is at least one gluconeogenic enzyme strongly regulated (decreased expression after feeding) in the two fish species, i.e. the PEPCK for common carp and G6Pase/FBPase for gilthead seabream. In these fish species, the regulation seems to be similar to the mammals at least at the molecular level. 相似文献
17.
18.
E. A. Burenina 《Journal of Evolutionary Biochemistry and Physiology》2009,45(5):571-578
There were studied activities and properties of mitochondrial and microsomal glucose6-phosphatases (G6Pases) in the free-living
turbellarian Phagocata sibirica and cestode Bothriocephalus scorpii. Action of various effectors (sodium fluoride, glucose, HCO3, citrate, Cu2+, DTT, EDTA, ATP, ADP) on the enzyme activity was studied. The obtained results and literature data demonstrate that G6Pase
is present in various muscles of different representatives of the animal kingdom. The conclusion could be made that invertebrate
G6Pase releases glucose from glycogen and gluconeogenic precursors. 相似文献
19.
20.
Troglitazone is an oral insulin-sensitizing drug used to treat patients with type 2 diabetes. A major feature of this hyperglycemic state is the presence of increased rates of hepatic gluconeogenesis, which troglitazone is able to ameliorate. In this study, we examined the molecular basis for this property of troglitazone by exploring the effects of this compound on the expression of the two genes encoding the major regulatory enzymes of gluconeogenesis, phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) in primary cultures of rat hepatocytes. Insulin is able to inhibit expression of both of these genes, which was verified in our model system. Troglitazone significantly reduced mRNA levels of PEPCK and G6Pase in rat hepatocytes isolated from normal and Zucker-diabetic rats, but to a lesser extent than that observed with insulin. Interestingly, troglitazone was unable to reduce cAMP-induced levels of PEPCK mRNA, suggesting that the molecular mechanism whereby troglitazone exerted its effects on gene expression differed from that of insulin. This was further supported by the observation that troglitazone was able to reduce PEPCK mRNA levels in the presence of the insulin signaling pathway inhibitors wortmannin, rapamycin, and PD98059. These results indicate that troglitazone can regulate the expression of specific genes in an insulin-independent manner, and that genes encoding gluconeogenic enzymes are targets for the inhibitory effects of this drug. 相似文献